Boston (SmartAboutHealth) - According to recent news, the experimental Eli Lilly and Co. drug for schizophrenia has failed recent tests in order to prove that it performs better than current medicine.

Although the drug showed promising results 2 years earlier, the drug maker announced on Sunday that the drug performed inconclusively in a Phase II clinical trial.

The Indianapolis drug maker had hoped that the new drug; LY2140023, would be a breakthrough treatment for schizophrenia, a mental illness that affects millions of Americans.

Tested on 200 patients in earlier studies, the drug worked relatively quickly and safely without resulting in weight gain. Weight gaining was a highly criticized side effect of its top-selling anti-psychotic drug, Zyprexa.

The latests tests on 393 patients showed that the drug failed to outperform Zyprexa.

Lilly said it will continue to develop and test the drug.